177 related articles for article (PubMed ID: 31570853)
21. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
22. Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer.
Kunder R; Velyunskiy M; Dunne SF; Cho BK; Kanojia D; Begg L; Orriols AM; Fleming-Trujillo E; Vadlamani P; Vialichka A; Bolin R; Perrino JN; Roth D; Clutter MR; Zielinski-Mozny NA; Goo YA; Cristofanilli M; Mendillo ML; Vassilopoulos A; Horiuchi D
Cell Chem Biol; 2022 Mar; 29(3):358-372.e5. PubMed ID: 34525344
[TBL] [Abstract][Full Text] [Related]
23. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
24. A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from PML-induced Senescence.
Acevedo M; Vernier M; Mignacca L; Lessard F; Huot G; Moiseeva O; Bourdeau V; Ferbeyre G
Cancer Res; 2016 Jun; 76(11):3252-64. PubMed ID: 27206849
[TBL] [Abstract][Full Text] [Related]
25. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
[TBL] [Abstract][Full Text] [Related]
26. PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer.
Mahata S; Sahoo PK; Pal R; Sarkar S; Mistry T; Ghosh S; Nasare VD
Med Oncol; 2022 May; 39(5):74. PubMed ID: 35568774
[TBL] [Abstract][Full Text] [Related]
27. Noninvasive
Henry KE; Dilling TR; Abdel-Atti D; Edwards KJ; Evans MJ; Lewis JS
J Nucl Med; 2018 Jan; 59(1):51-57. PubMed ID: 28848040
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
[TBL] [Abstract][Full Text] [Related]
29. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
30. Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer.
He Q; Xue S; Tan Y; Zhang L; Shao Q; Xing L; Li Y; Xiang T; Luo X; Ren G
Cancer Lett; 2019 Apr; 448():94-104. PubMed ID: 30742942
[TBL] [Abstract][Full Text] [Related]
31. Suppression of RAD21 Induces Senescence of MDA-MB-231 Human Breast Cancer Cells Through RB1 Pathway Activation Via c-Myc Downregulation.
Zhu S; Zhao L; Li Y; Hou P; Yao R; Tan J; Liu D; Han L; Huang B; Lu J; Zhang Y
J Cell Biochem; 2016 Jun; 117(6):1359-69. PubMed ID: 26529363
[TBL] [Abstract][Full Text] [Related]
32. Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling.
Hubackova S; Novakova Z; Krejcikova K; Kosar M; Dobrovolna J; Duskova P; Hanzlikova H; Vancurova M; Barath P; Bartek J; Hodny Z
Cell Cycle; 2010 Aug; 9(15):3085-99. PubMed ID: 20699642
[TBL] [Abstract][Full Text] [Related]
33. Androgen Receptor and
Ntzifa A; Strati A; Koliou GA; Zagouri F; Pectasides D; Pentheroudakis G; Christodoulou C; Gogas H; Magkou C; Petraki C; Kosmidis P; Aravantinos G; Kotoula V; Fountzilas G; Lianidou E
Cancer Genomics Proteomics; 2021; 18(2):147-156. PubMed ID: 33608311
[TBL] [Abstract][Full Text] [Related]
34. c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor.
Chandramohan V; Mineva ND; Burke B; Jeay S; Wu M; Shen J; Yang W; Hann SR; Sonenshein GE
J Cell Biochem; 2008 Aug; 104(6):2091-106. PubMed ID: 18393360
[TBL] [Abstract][Full Text] [Related]
35. Study of Arsenic Sulfide in Solid Tumor Cells Reveals Regulation of Nuclear Factors of Activated T-cells by PML and p53.
Ding W; Tong Y; Zhang X; Pan M; Chen S
Sci Rep; 2016 Jan; 6():19793. PubMed ID: 26795951
[TBL] [Abstract][Full Text] [Related]
36. Gallic acid induces G1 phase arrest and apoptosis of triple-negative breast cancer cell MDA-MB-231 via p38 mitogen-activated protein kinase/p21/p27 axis.
Lee HL; Lin CS; Kao SH; Chou MC
Anticancer Drugs; 2017 Nov; 28(10):1150-1156. PubMed ID: 28938245
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo.
Park SH; Chung YM; Ma J; Yang Q; Berek JS; Hu MC
Oncotarget; 2016 Jul; 7(27):42110-42125. PubMed ID: 27283899
[TBL] [Abstract][Full Text] [Related]
38. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
39. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
[TBL] [Abstract][Full Text] [Related]
40. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
